Blood
Articles in this Issue
Total metabolic tumor volume as a prognostic biomarker in high-burden follicular lymphoma: A systematic review and meta-analysis
Abstract Background: Follicular lymphoma is an indolent disease characterized by clinical diversity. The Follicular Lymphoma International P...
Trends and disparities in atrial fibrillation and anemia-related mortality in adults aged ≥ 25 years in the United States from 1999 to 2023: A CDC wonder database analysis
Abstract Introduction: Atrial fibrillation and anemia are both common in the United States and are interrelated. There is emerging evidence...
Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)
Abstract Introduction: Bispecific antibodies (BsAbs) targeting B-cell maturation antigen (BCMA) and G protein coupled-receptor, class C group...
γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction
Abstract Background: AML impairs immunosurveillance and cytotoxic T-cell responses. γ9δ2TCs are known to drive anti-leukemia benefit in the...
Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis
Abstract Introduction Obecabtagene autoleucel (obe-cel) and brexucabtagene autoleucel (brexu-cel) are CD19 targeted chimeric antigen recepto...
Early PET response for relapse prediction in 2nd or higher line lisocabtagen maraleucel in large B-cell lymphoma
Abstract Introduction: Anti-CD19 CAR-T-cell therapy (CART) is highly effective in relapsed/refractory (r/r) large B-cell lymphoma (LBCL) and...
Development and multicenter evaluation of a novel 12-color flow cytometric antibody panel and dedicated analysis algorithm for fully standardized automated measurable residual disease (MRD) detection in chronic lymphocytic leukemia (CLL) at a sensitivity of at least 10E-5
Abstract Introduction As flow cytometric MRD is increasingly used to tailor treatment according to the needs of individu...
Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response
Abstract Tyrosine kinase inhibitor (TKI) discontinuation, also known as treatment-free remission (TFR) is currently one of the main goals of...
A rare case of influenza associated immune thrombotic thrombocytopenia purpura in a pediatric patient
Abstract Introduction Immune thrombotic thrombocytopenic purpura (iTTP) is an ultra-rare thrombotic microangiopathy (TMA...
Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience
Abstract Background: T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) poses significant therapeutic challenges in...
Correlation between interleukin (IL)-8 and tumor necrosis factor (TNF)-alpha levels and overall survival in patients (pts) with myelofibrosis (MF) relapsed or refractory (R/R) to a Janus-associated kinase inhibitor (JAKi) treated with imetelstat (IME) in the imbark trial
Abstract Introduction: The dysregulation of inflammatory cytokines plays a key role in the pathogenesis, progression, and clinical features...
Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients (pts) with chronic Phase-chronic myeloid leukemia (CP-CML)
Abstract Introduction Olverembatinib, a third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI), has demonstrated remarkable efficacy and a...
Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia
Abstract Background: Undetectable minimal residual disease (uMRD) at the end of first-line (1L) treatment (tx) with 12-cycles (C) of venetocl...
Differences in peripheral neuropathy reports by race informed by electronic patient-reported outcomes (ePROs) deployed in multiple myeloma (MM) clinical practice
Abstract Background: Past study has shown that African Americans are over twice as likely to be diagnosed with MM than Whites (Padala et al....
Fibrinogen concentrate versus cryoprecipitate for bleeding in cardiac surgery patients stratified by surgery risk in the phase 3 fibres Study
Abstract Introduction The Phase 3 FIBRES study demonstrated that fibrinogen concentrate (FC) was non-inferior to cryoprecipitate for the tre...
Dynamic monitoring of circulating tumor DNA for real-time risk assessment in early-stage natural killer/t-cell lymphoma
Abstract BackgroundAlthough early-stage natural killer/T-cell lymphoma (NKTCL) typically responds to radiation therapy (RT) and asparaginase...
Impact of bortezomib on T-cell subsets and immune checkpoints under bispecific antibody therapy in multiple myeloma
Abstract Background The combination of proteasome inhibitors (PI) and bispecific antibodies (bsAb) has demonstrated both synergistic and pot...
Multicenter propensity score matched study on allogeneic stem cell transplantation in adult sickle cell disease: Comparison of donor vs. no donor outcomes
Abstract Background Despite the lack of high-level scientific evidence, allogeneic hematopoietic stem cell transplantation (Allo HPSCT) is r...
Diagnostic and prognostic value of 18f-florbetapir PET/CT in systemic light-chain amyloidosis.
Abstract Introduction: Systemic light-chain (AL) amyloidosis is a heterogeneous group of disorders caused by misfolding and aggregation prot...
Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy
Abstract Background: Mutations in the isocitrate dehydrogenase 1 gene (mIDH1) occur in a subset (7%-14%) of patients with acute myeloid leuk...
Targeting ribonucleotide reductase to overcome FLT3 Inhibitor Resistance in acute myeloid leukemia
Abstract Acute myeloid leukemia (AML), the most common acute leukemia in adults, is frequently characterized by chemotherapy resistance and...
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Abstract Introduction: Covalent Bruton tyrosine kinase inhibitors (cBTKi) are a mainstay of chronic lymphocytic leukemia/small lymphocytic l...
Novel gsdmd agonist dmb induces synergistic pyroptosis and apoptosis in diffuse large B-cell lymphoma
Abstract Background: Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is characterized by high hetero...
Caspase-4/11 alters circulating immune cells and mediates organ damage in Townes SCD mice
Abstract Sickle cell disease (SCD) is an inherited red blood cell disorder that is characterized by constant lysis of red blood cells and su...
Novel use of a privacy-preserving hashed identifier to match individuals in different sickle cell disease registries and assess acute care utilization
Abstract Introduction: Sickle cell disease (SCD) is the most common inherited clinically relevant blood disorder resulting in several compli...